acute myeloid leukemia

New interactions between two molecules involved in acute myeloid leukemia (AML) have been found by scientists that may offer a new therapeutic TUESDAY, June 9 (HealthDay News) For most patients with (AML) who come out of remission, donor stem cells appear to offer TUESDAY, June 9 (HealthDay News) For most patients with acute leukemia (AML) who come out of remission, donor stem cells appear to offer Longtime Turner Sports broadcaster Craig Sager died Thursday from myeloid He was 65. Turner Sports announced the news with the A novel mouse model of a highly lethal form of acute myeloid leukemia (AML) offers a new tool for scientists working to better understand this Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat myeloid (AML) are very promising.


Patients of researchers has demonstrated that a molecule isolated from sea sponges and later synthesized in the lab, can halt the growth of acute myeloid leukemia ( AML ), also known as acute myelogenous or acute nonlymphocytic leukemia ( ANLL ), is a cancer of the The chemotherapy treatments necessary to treat (AML) in children can be grueling on the body, and can cause health-related A tumor suppressor protein thought to prevent myeloid leukemia (AML) can actually promote a particularly deadly form of the disease, researchers a set of genes, including DNMT3A, that could potentially be used to predict clinical outcomes of patients who suffer from a type of Myeloid The mechanism that gene MN1 uses to cause an aggressive AML subtype is better understood thanks to new research.


Drugs targeting weak link in Scientists have discovered why leukemias with the same genetic abnormality vary in their aggressiveness based on their cellular origin. A promising new approach to the treatment of (AML) has been discovered by a team of researchers. In their report, the Scientists have discovered that a certain class of receptors that inhibit immune response are crucial for the development of A study of the gene BAALC and the smaller gene miR-3151 embedded within it finds the smaller one is the major driver of acute leukemia A new clue has been found that may help fight acute myeloid leukemia (AML), the most common form of cancer of the blood and bone marrow, and Additional findings explain the development of about one-third of AML cases and may contribute towards AML diagnostic applications and drug screening.

.

acute myeloid leukemia

acute myeloid leukemia

High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells
L Poulain, P Sujobert, F Zylbersztejn, S Barreau, L Stuani, M Lambert, T L Palama, V Chesnais, R Birsen, F Vergez, T Farge, C Chenevier-Gobeaux, M Fraisse, F Bouillaud, C Debeissat, O Herault, C Récher, C Lacombe, M Fontenay, P Mayeux, T T Maciel, J-C

49-year-old man with sinus tachycardia
A 49-year-old man with acute myeloid leukemia on chemotherapy with new sinus tachycardia. To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Scientists show p300 protein may stop MDS from developing into leukemia
The study was published in the journal Leukemia. "The loss of p300 allows these defective cells to grow and become leukemic," said Sylvester Director Stephen Nimer, M.D., principal investigator of the study. "This work offers us a window into AML

Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia
HOUSTON, TX--(Marketwired - March 22, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license

Medidata Clinical Cloud Selected for AML Master Trial by LLS
Medidata Solutions Inc. MDSO recently announced that The Leukemia & Lymphoma Society (“LLS”) has selected its flagship Medidata Clinical Cloud platform for diagnosis and treatment of acute myeloid leukemia (AML) through a clinical trial known as the

Your name (required)
Your e-mail (required)